Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 16;35(10):e63.
doi: 10.3346/jkms.2020.35.e63.

Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?

Gökmen Asan  1 , Mehmet Emin Derin  2 , Halef Okan Doğan  3 , Meliha Bayram  1 , Mehtap Şahin  3 , Ali Şahin  4
Affiliations

Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients?

Gökmen Asan et al. J Korean Med Sci. .

Abstract

Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease that has self-limiting inflammatory attacks during polyserositis. Hepcidin is a protein, and interleukin-6 stimulation increases hepcidin levels. Calprotectin (CLP) is a recently defined cytokine released from monocytes and neutrophils in response to tissue trauma and inflammation. There are studies in the literature showing that it can be used as a biomarker in rheumatic diseases such as ankylosing spondylitis and rheumatoid arthritis. Here, we compared the levels of hepcidin and CLP in healthy individuals and FMF patients during an attack-free period and show its relation to genetic mutations.

Methods: This is a cross-sectional study. Between July 2017 and December 2017, 60 patients diagnosed with FMF an admitted to the Cumhuriyet University Faculty of Medicine Department of Internal Medicine Rheumatology as well as 60 healthy volunteers without any rheumatic, systemic, or metabolic diseases were enrolled in this study. Blood was collected from a peripheral vein to measure serum CLP and hepcidin levels. Blood tests were examined by ELISA; the study protocol was approved by the local ethics committee.

Results: Median serum hepcidin level was 468.1 (210.3-807.8) pg/mL in FMF group and 890.0 (495.0-1,716.9) pg/mL in the healthy control (HC) group. There was a statistically significant difference between the two groups (P < 0.001). The median serum levels of CLP in the FMF group were measured as 1,331.4 (969.3-1,584.6 pg/mL and 73.8(45.0-147.9) pg/mL in the HC group. There was a statistically significant difference between the two groups (P < 0.001). Receiver operating characteristic analysis showed that the sensitivity was 66.7% and the specificity was 71.7% at serum hepcidin < 581.25 pg/mL (P < 0.05); the sensitivity was 96.7% and specificity was 100% at CLP > 238 pg/mL (P < 0.05). There was no significant difference between serum hepcidin and CLP levels in FMF patients with M694V homozygous and M694V heterozygous (P > 0.05). There was no significant difference in serum hepcidin levels between FMF patients with and without arthritis, proteinuria, and amyloidosis (P < 0.05). There was no significant correlation between laboratory findings, gender, age, and serum CLP and hepcidin levels (P > 0.05, r < 0.25).

Conclusion: Serum CLP levels in FMF patients during an attack-free period are significantly higher than in the HC groups. Serum hepcidin levels in FMF patients are significantly lower than in the HC group. Low levels of hepcidin may be explained by including FMF patients during an attack-free period in the study. CLP may be an important biomarker in FMF. A better understanding of the role of these biomarkers in the diagnosis of FMF is needed to evaluate the results in a more comprehensive way.

Keywords: Calprotectin; FMF; Hepcidin.

PubMed Disclaimer

Conflict of interest statement

The authors have no potential conflicts of interest to disclose.

Figures

Fig. 1
Fig. 1. Serum hepcidin levels in FMF patients and control group.
FMF = familial Mediterranean fever.
Fig. 2
Fig. 2. Serum CLP levels in FMF patients and control group.
FMF = familial Mediterranean fever, CLP = calprotectin.
See this image and copyright information in PMC

References

    1. Erken E, Erken E. Cardiac disease in familial Mediterranean fever. Rheumatol Int. 2018;38(1):51–58. - PubMed
    1. Migita K, Agematsu K, Yazaki M, Nonaka F, Nakamura A, Toma T, et al. Familial Mediterranean fever: genotype-phenotype correlations in Japanese patients. Medicine (Baltimore) 2014;93(3):158–164. - PMC - PubMed
    1. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93(1):90–97. - PubMed
    1. Baflol G, Barutçuoğlu B, Bozdemir AE. Demir homeostazının yeni düzenleyicisi hepsidin hepcidin, a new regulator of iron homeostasis. Turk Klin Biyokim Derg. 2007;5(3):117–125.
    1. Kim HR, Kim KW, Yoon SY, Kim SH, Lee SH. Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis. J Korean Med Sci. 2010;25(3):348–352. - PMC - PubMed